Considering the dynamic expression of MITF in response to changing microenvironmental conditions at various phases of melanomagenesis, MITF levels can be considered as a predictive marker for a suitable therapy regimen for treating a particular melanoma phase. This evidence concerns the gene MITF and melanoma.